These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 22471520)
41. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors. Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814 [TBL] [Abstract][Full Text] [Related]
42. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer]. Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747 [TBL] [Abstract][Full Text] [Related]
43. The role of S100A14 in epithelial ovarian tumors. Cho H; Shin HY; Kim S; Kim JS; Chung JY; Chung EJ; Chun KH; Hewitt SM; Kim JH Oncotarget; 2014 Jun; 5(11):3482-96. PubMed ID: 24939856 [TBL] [Abstract][Full Text] [Related]
44. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors. Gianazza E; Chinello C; Mainini V; Cazzaniga M; Squeo V; Albo G; Signorini S; Di Pierro SS; Ferrero S; Nicolardi S; van der Burgt YE; Deelder AM; Magni F J Proteomics; 2012 Dec; 76 Spec No.():125-40. PubMed ID: 22868251 [TBL] [Abstract][Full Text] [Related]
45. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Giurgea LN; Ungureanu C; Mihailovici MS Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020 [TBL] [Abstract][Full Text] [Related]
46. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402 [TBL] [Abstract][Full Text] [Related]
47. The ascites N-glycome of epithelial ovarian cancer patients. Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862 [TBL] [Abstract][Full Text] [Related]
49. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy. Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197 [TBL] [Abstract][Full Text] [Related]
50. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma. Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000 [TBL] [Abstract][Full Text] [Related]
51. Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer. Podzielinski I; Saunders BA; Kimbler KD; Branscum AJ; Fung ET; DePriest PD; van Nagell JR; Ueland FR; Baron AT Cancer Invest; 2013 May; 31(4):258-72. PubMed ID: 23627408 [TBL] [Abstract][Full Text] [Related]
52. Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry. Kim NA; Jin JH; Kim KH; Lim DG; Cheong H; Kim YH; Ju W; Kim SC; Jeong SH Arch Pharm Res; 2016 May; 39(5):668-76. PubMed ID: 27002828 [TBL] [Abstract][Full Text] [Related]
53. The functional proteomics analysis of VEGF-treated human epithelial ovarian cancer cells. Zhang F; Li C; Liu H; Wang Y; Chen Y; Wu X Tumour Biol; 2014 Dec; 35(12):12379-87. PubMed ID: 25192722 [TBL] [Abstract][Full Text] [Related]
54. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours. Saied EM; El-Etreby NM Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363 [TBL] [Abstract][Full Text] [Related]
55. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325 [TBL] [Abstract][Full Text] [Related]
56. [Expressions of Ki67, PCNA and mitotic index in ovarian epithelial tumors]. Wang S; Ma XY; Xia Y; Zhang LH Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 41(4):575-80. PubMed ID: 20848772 [TBL] [Abstract][Full Text] [Related]
57. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions. Ye F; Hu Y; Zhou C; Hu Y; Chen H Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257 [TBL] [Abstract][Full Text] [Related]
58. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125 [TBL] [Abstract][Full Text] [Related]
59. Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. Zhuang H; Gao J; Hu Z; Liu J; Liu D; Lin B PLoS One; 2013; 8(7):e68994. PubMed ID: 23894390 [TBL] [Abstract][Full Text] [Related]
60. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Yoshioka S; King ML; Ran S; Okuda H; MacLean JA; McAsey ME; Sugino N; Brard L; Watabe K; Hayashi K Mol Cancer Res; 2012 Mar; 10(3):469-82. PubMed ID: 22232518 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]